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BACKGROUND: Radiofrequency ablation (RFA) has been widely applied for the treatment of hepato-
cellular carcinoma and liver metastases. The reported mortality and morbidity rates are low. The aim of
this study is to evaluate the safety and efficacy of RFA, and compare the results performed percutaneously
versus surgically.
PATIENTS AND METHODS: From 2003 to 2006, 79 patients with hepatic malignancies (59 hepato-
cellular carcinoma, 20 liver metastases) with a total of 110 lesions underwent RFA in our centre. Post-
ablation assessment by CT scan was performed in all patients at 1-, 3- and 6-month intervals.
Post-procedural complications, recurrence and survival were analysed.
RESULTS: The patients’ mean age was 60.0 years. In 46.8% of cases, we used a percutaneous approach; in
53.2% of cases, a surgical approach (8.9% laparoscopic; 44.3% open) was used if percutaneous approach
was not feasible. The mean tumour size was 2.4 cm. Within the surgical group, 69% of patients received
concomitant operative procedures such as cholecystectomy and hepatectomy. No treatment-related mor-
tality was observed. Immediate complications occurred in five patients (6.3%), including gastric serosal
burn (n = 1), ground pad superficial skin burn (n = 1), intra-abdominal bleeding (n = 2) and pleural effusion
(n = 1). All patients except one attended subsequent follow-up, with a mean period of 16 months. Ablation
was considered complete in 82.3% of patients (percutaneous approach 81.1%, surgical approach 83.3%,
p =0.72). Intrahepatic recurrence was observed in 52.3%, the majority of them located away from the RFA site.
Extrahepatic recurrences were observed in 16.9% (percutaneous approach 16.7%, surgical approach 17.1%,
p = 0.76). The overall one- and two-year survival rate was 93.7% and 74.4% respectively, and no statistically
significant difference was observed between the two approaches.
CONCLUSION: RFA is a safe and effective procedure for treating patients with malignant liver tumours.
No difference in short term outcomes was observed between percutaneous and surgical approaches. A more
prolonged follow-up study is required to assess longer-term outcomes. [Asian J Surg 2009;32(1):13–20]
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Introduction
In recent years, there has been growing interest in
radiofrequency ablation (RFA) for treating liver tumours.
This has been widely accepted as an effective modality for
treating unresectable hepatocellular carcinoma (HCC)
and liver secondaries.1–4 It is a thermoablative technique,
based on the conversion of radiofrequency waves into
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heat, and thus generating areas of coagulative necrosis
and tissue desiccation.5 The ablation can be performed
percutaneously, laparoscopically, thoracoscopically, or at
open surgery.6 Variable oncological outcomes have been
reported by means of different approaches.7,8 Nowadays,
RFA is widely applied to patients with small tumours with
encouraging results9 and its reported mortality and 
morbidity has been low.10
In our locality, where chronic hepatitis B virus (HBV)
infection and cirrhosis of liver are commonly seen, the
incidence of HCC is particularly high. The prognosis of
HCC is generally poor. Liver resection remains the “gold
standard” for curative treatment, but is suitable only for
minority of patients.11 Similarly, up to 80% of patients
with colorectal liver metastasis are considered not a can-
didate for surgical treatment.12 We performed RFA on
patients with unresectable disease either percutaneously
or surgically. The objective of this study was to evaluate
the safety and efficacy of RFA in treating hepatic malig-
nancies. The outcome performed via these two approaches
was compared.
Patients and methods
From May 2003 to February 2006, 79 patients (60 men
and 19 women) undergoing RFA for malignant liver
tumours in our centre were evaluated. Patients’ demo-
graphics and tumour characteristics are listed in Table 1.
The patients’ mean age was 60 years (range, 37–93). The
nature of malignancy included hepatocellular carcinoma
(59 cases) and hepatic metastasis (20 cases). A total of 110
lesions were ablated.
Pre-procedural assessment
All patients were assessed clinically and investigated with
laboratory tests of liver functions, hepatitis B/C serology,
alpha-fetoprotein and carcinoembryonic antigen. Radio-
logically, they all had a chest X-ray and a trans-abdominal
ultrasound, followed by a 3-phase contrast computed
tomography (CT) scan. In situations where a malignant
nature was uncertain, liver biopsy was performed prior to
ablation. Benign conditions were excluded. Standard car-
diopulmonary assessments and indocyanine green (ICG)
clearance tests were performed if a surgical approach was
contemplated.
All RFA procedures were performed either percuta-
neously or surgically (laparoscopic or open). Parameters
taken into consideration when planning the approach
included tumour size, number and location, previous
operations, general anaesthetic risk as well as the neces-
sity for concomitant operative procedures, such as a
cholecystectomy. If feasible, a percutaneous approach
remained the first choice of treatment, followed by a
laparoscopic approach and open surgery.
Patient selection criteria for RFA followed published
recommendations.6 RFA lesions were deemed unsuitable
for curative-intent liver resection due to poor hepatic
reserve (i.e. ICG retention at 15 minutes greater than 14%)
except in one resectable case, of which the patient refused
hepatectomy. The maximum dimension of the tumours
was not greater than 5 cm on CT scan measurement.
There was no evidence of extrahepatic metastasis upon
diagnosis. Subcapsular tumours, perivascular tumours
and tumours located too close to major bile ducts were
considered unsafe for percutaneous approach, and a 
surgical approach would be adopted instead.
A laparoscopic approach would be chosen for tumours
close to the gallbladder, where a laparoscopic cholecys-
tectomy would be performed in conjunction with the
RFA. For tumours located in the posterior aspect of 
the left lobe, the stomach could be insulated from the
RFA site by a wet gauze or cold saline. The whole abdomi-
nal cavity could also be carefully inspected to exclude
peritoneal metastasis. An open approach would be in-
dicated for patients with previous abdominal surgery, 
or tumours in close proximity to surrounding organs 
that required meticulous adhesiolysis. Open approach
would be necessary if the tumour was located at the right
posterior sector, where full mobilisation of the right 
lobe was needed. The degree of freedom for introduction
of the RFA needle into the target was also taken into 
consideration.
RFA ablation technique
Percutaneous RF ablations were performed by consultant
interventional radiologists. Surgical RFA procedures were
performed by the same team of hepato-biliary surgeons.
Ablation techniques were standardised according to rec-
ommended protocols provided by the manufacturers
(Boston Scientific and Tyco Healthcare).
Percutaneous RFA was performed under local anaes-
thesia with conscious sedation. Para-vertebral block was
given in selected cases. Tumour localisation and ablation
were guided by abdominal ultrasound or CT scan or by
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both modalities. RF 3000 Radiofrequency Generator with
LeVeen needles (Boston Scientific, USA) was used in
almost all cases, aiming at a 0.5–1.0 cm margin around
the tumour. If the nature of the lesion was not diagnosed
radiologically or biochemically, a liver biopsy through a
co-access needle system was performed immediately prior
to ablation. Only malignant nodules were included in the
present study. Multiple overlapping zones of ablation
were needed in 50% of cases in order to achieve adequate
coverage with margins. The needle track was burned at
the end of the procedure.
Laparoscopic RFA procedures were done with a 
30o laparoscope with CO2 pneumoperitoneum. After 
a full laparoscopy to exclude the presence of peritoneal
metastasis, the intrahepatic lesions were localised with
intra-operative laparoscopic ultrasound (linear array,
Aloka SSD-2000). A Radionics Cool-tip RF System (Tyco
Healthcare) was used. Multiple overlapping ablations
were performed when necessary to ensure ablation mar-
gins, as in the percutaneous group. The needle track was
burned at the end of ablation. Two patients in this group
also received concomitant laparoscopic cholecystectomy
(Table 2).
Open RFA procedures were performed via a right sub-
costal incision. After adequate mobilisation, tumour
localisation and electrode placement was guided by intra-
operative ultrasound (T-probe, Aloka SSD-2000). Ablation
was performed as described above. Both the Radionics
Cool-tip RF System (Tyco Healthcare) and RF 3000 Radio-
frequency Generator (Boston Scientific, USA) systems
were used, whichever more applicable. In general, LeVeen
needles (Boston Scientific, USA) were avoided in lesions
located peripherally. The Pringle manoeuvre was not
applied for all cases. Concomitant surgical procedures
were listed in Table 2.
Patients’ follow-up
All patients except one from the surgical group attended
subsequent follow-up visits, with a mean follow-up period
of 16 months (range, 2.1–38.5). Patients were assessed by
contrast-enhanced CT scans 1, 3 and 6 months after RFA.
The ablation response was defined as “incomplete” if
there was existence of arterial enhanced areas on the first
set of post-ablation imaging. For the completely ablated
cases, the presence of enhanced appearance on subsequent
scans was defined as “recurrence”. Intrahepatic recurrence
could be at the previously ablated sites or at distant sites.
Extrahepatic recurrences were detected by CT scans, chest
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Table 1. Patient demographics and tumour characteristics
Percutaneous Surgical p
Number of patients 37 42
Sex (M:F) 29:8 31:11
Age (yr) 63 (37–93) 56 (38–77)
Diagnosis (HCC:Liver metastases) 27:10 32:10
Number of tumours 39 71
Median no. of tumours ablated/patient 1.0 (1.0–2.0) 1.0 (1.0–7.0) 0.005*
Median tumour size (cm) 2.5 (1.3–5.0) 2.0 (0.5–8.0) 0.174
Median hospital stay (d) 4.0 (2.0–8.0) 8.0 (5.0–42.0) 0.001*
Median follow-up period (mo) 13.6 (3.5–26.6) 17.7 (2.1–38.5)
*p< 0.05, Mann-Whitney test. HCC = hepatocellular carcinoma.
Table 2. Concomitant surgical procedures during RFA (laparo-
scopic and open)
Type of surgery
Number of 
patients
Laparoscopic group 7
Cholecystectomy 2
Open group 35
Hepatectomy only 5
Cholecystectomy only 11
Hepatectomy & cholecystectomy 4
Excision of peritoneal nodules 2
Colectomy 1
Excision of liver haemangioma 1
Right adrenalectomy 1
Hernioplasty (Inguinal & paraumbilical) 1
Celiac lymph node dissection 1
X-rays, bone scans, PET scans or tissue histology in indi-
vidual cases. All patients on subsequent follow-up visits
had a clinical assessment by the surgical team with 
documentation of all complications.
Statistical analysis
Parameters including tumour number, tumour size,
length of hospital stay, procedure-related complications
and treatment outcome were analysed and data compared
between the percutaneous and surgical groups. Data were
expressed as mean ± SD. Non-parametric data were ex-
pressed as median (range) and tested by the Mann-Whitney
test. Survival data and tumour recurrence rates were cal-
culated using the Kaplan-Meier method and were com-
pared by the log rank test. The level of significance was set
at 0.05 for all tests.
Results
Tumour number and RFA approach
A total of 110 lesions were ablated in 79 patients. A per-
cutaneous approach was applicable in 46.8% of cases, a
laparoscopic approach in 8.9% and an open approach in
44.3% (surgical approach = 8.9% + 44.3% = 53.2%). The total
number of ablated lesions in the percutaneous group was
39, and for the surgical group the number was 71. The
median number of ablated lesions per patient in the per-
cutaneous group was 1.0 (range, 1.0–2.0), as compared to
1.0 (range, 1.0–7.0) in the surgical group.
Tumour size
The median tumour size was 2.5 cm (range, 1.3–5.0) in 
the percutaneous group; and 2.0 cm (range, 0.5–8.0) in
the surgical group. The difference was not statistically 
significant (p = 0.174).
Length of hospital stay
The median length of hospital stay in the percutaneous
group was 4 days (range, 2–8); compared to 8 days (range,
5–42) in the surgical group, and the difference was statis-
tically significant (p = 0.001).
Complications (Table 3)
Five patients (6.3%) suffered from immediate procedural-
related complications (Table 3). In the percutaneous group,
one patient developed mild perihepatic bleeding and one
patient had pleural effusion, both resolved on conserva-
tive management. In the surgical group, immediate com-
plications included superficial skin burns at the ground
pad site (n = 1), bleeding from the right adrenal (n = 1) and
serosal burns of the anterior wall of the stomach (n = 1).
These were all identified intra-operatively. No treatment-
related mortality was documented in any of the patients.
Post-ablation fever was noted in 20.3% of the overall
patients. The majority of them responded well to a course
of non-steroidal anti-inflammatory drugs. Prescription of
antibiotics was restricted to those with evidence of leuko-
cytosis or clinical signs of sepsis. Needle-track seeding was
identified in one patient 9 months after percutaneous
RFA. All complications were summarised in Table 3.
Treatment outcome (Tables 4 and 5)
Complete ablation, as defined by no viable tumour detect-
able on the first set of CT scans 1 month after ablation,
was achieved in 82.3%. There was no significant difference
between the percutaneous (81.1%) and the surgical group
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Table 3. Complications of RFA
Percutaneous Surgical
Immediate Perihepatic bleeding (n= 1) Right adrenal haemorrhage (n= 1) n.s.
Pleural effusion (n= 1) Superficial skin burn (n= 1)
Gastric serosal burn (n= 1)
Early Nil Chest infection (n= 1) p= 0.057
Wound infection (n= 1)
Ascites (n= 1)
Atrial fibrillation (n= 1)
Supra-ventricular tachycardia (n= 1)
Delay Needle-track seeding (n= 1) Nil n.s.
Fisher’s exact test. n.s. = not significant.
(83.3%) (p = 0.717). Subgroup analysis demonstrated no
difference in outcome with regard to the primary pathology
(i.e. HCC or liver metastasis).
The overall intrahepatic recurrence rate was 52.3%.
Only a minority occurred at the previous RFA site (percu-
taneous approach 10.0%, surgical approach 2.9%, p = 0.195);
while the majority occurred at a distant site (percutaneous
approach 43.3%, surgical approach 54.3%, p = 0.918).
Extrahepatic recurrence was documented in 16.9% of
all patients in this series (Table 6). Again, there was no sig-
nificant difference between the two groups (percutaneous
approach 16.7%; surgical approach 17.1%, p = 0.756).
Overall, patients had a median follow-up period of
14.3 months (range, 2.1–38.5) after RFA (percutaneous
group 13.6 months, range, 3.5–26.6; surgical group 17.7
months, range, 2.1–38.5). Survival curves were shown in
Figure. The overall 1-year survival was 93.7%, (97.3% in the
percutaneous group, 90.5% in the surgical group). The
overall 2-year survival was 74.4%, (79.8% in the percuta-
neous group, 70.8% in the surgical group). There was no
significant difference in terms of survival between the two
approaches (p = 0.644). One- and 2-year survival rates of
HCC patients and liver metastasis patients after RFA are
listed in Table 5. The number of patients in each sub-
group was too small for meaningful survival analysis and
comparison.
Discussion
The two most commonly encountered liver malignancies
in our locality are hepatocellular carcinoma and colorec-
tal liver metastases. While surgical resection remains the
“gold standard” for treating both conditions, only a small
proportion of patients are suitable candidates for curative-
intent hepatectomy.11 This may be due to patient’s comor-
bidity, poor liver reserve, presence of extrahepatic disease,
or it may be related to the number and anatomical loca-
tion of the tumours. Radiofrequency ablation has become
one of the best alternatives in treating these patients who
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Table 5. Survival of HCC and liver metastases patients treated
by percutaneous and surgical approach
Percutaneous Surgical
HCC (n= 27) (n= 32)
1-year survival (%) 96.3 87.5
2-year survival (%) 96.3 66.0
Liver metastases (n= 10) (n= 10)
1-year survival (%) 100.0 100.0
2-year survival (%) 42.9 85.7
HCC = hepatocellular carcinoma.
Table 6. Sites of extrahepatic recurrence in the 11 patients
Sites Number of patients (%)
Lung 6 (54.5)
Bone 3 (27.3)
Adrenal 2 (18.2)
Skin 2 (18.2)
Peritoneum 2 (18.2)
Mesocolon 2 (18.2)
Lymph nodes 1 (9.1)
Spleen 1 (9.1)
Omentum 1 (9.1)
Kidney 1 (9.1)
Small bowel mesentery 1 (9.1)
Table 4. Summary of RFA treatment outcome
Percutaneous Surgical p
Complete ablation (%) 81.1 83.3 0.717
HCC 81.5 84.4
Liver metastases 80.0 80.0
Intrahepatic recurrence (%)
RFA site 10.0 2.9 0.195
Distant site 43.3 54.3 0.918
Extrahepatic recurrence (%) 16.7 17.1 0.756
1-year survival (%) 97.3 90.5
2-year survival (%) 79.8 70.8
HCC = hepatocellular carcinoma.
are not candidates for curative hepatectomy. A recent sys-
tematic review by Sutherland et al concluded that RFA
generally resulted in larger and more complete areas of
ablation, and RFA may also be associated with higher sur-
vival rates than the other ablative techniques being
assessed.1,13,14 The objective of this study is to evaluate the
safety and efficacy of RFA performed in our centre. The
results performed percutaneously and surgically were
analysed.
The choice between percutaneous and surgical (open
or laparoscopic) approaches deserves a careful discussion.
The percutaneous approach obviously has the advantage
of avoiding general anaesthesia and a surgical wound. It
can also be applied repeatedly to treat recurrent tumours.
Moderate to severe pain during the procedure was com-
monly encountered, but we have overcome this problem
by the addition of a para-vertebral block immediately
prior to the procedure. The percutaneous approach is less
invasive and the patients’ length of hospital stay was 
significantly shorter in our study. A very similar result was
demonstrated in the Italian group.15 The procedure may be
guided by a transabdominal ultrasound or CT scan, and
in majority of cases, we used both modalities simultane-
ously to maximise the accuracy in tumour localisation.
Nevertheless, certain limitations prevent interven-
tional radiologists applying the RFA electrode and target
at the lesion through the percutaneous route. These
include tumours that lie too peripherally and too close to
the diaphragm, major blood vessels or hollow organs such
as the bowel or gallbladder.16 Under these circumstances,
open surgical approach allows greater flexibility, both in
the placement of an intra-operative ultrasound trans-
ducer as well as the RFA electrode. The laparoscopic RFA
technique offers certain advantages over both percuta-
neous and open RFA.16 However, this minimally invasive
approach is more technically demanding, especially dur-
ing tumour localisation by the laparoscopic ultrasound
and insertion of the RFA electrode.
Another advantage of the surgical approach is that
concomitant procedures can be performed during RFA.
In the present series, a majority of the procedures were
cholecystectomies (n = 17) and liver resections (n = 9). The
gallbladders were removed not merely for those who had
concurrent symptomatic gallstones; this also facilitates
ablation of liver tumours located near to the gallbladder
bed. A combined approach using RFA with liver resec-
tions has been reported with encouraging results.17,18
We find this approach particularly useful for bilobar
lesions located in the peripheral segments. The prolonged
hospital stay in the surgical group (8 days) can be account-
able by the longer surgical wound and a greater magni-
tude of surgery, as compared to the percutaneous group
(4 days).
There have been postulations that the Pringle
manoeuvre during surgical RFA prevents dissipation of
heat from a vascular tumour and thus improves the like-
lihood of complete ablation.16 However, using a pig
model, Shen et al demonstrated that laparoscopic RFA
with the Pringle manoeuvre in proximity to major vascu-
lar structures did not significantly increase ablation size,
or cause vascular injury.19 In our series, the Pringle
manoeuvre was not performed in all cases.
It has been recommended that the efficacy of percu-
taneous ablation should be assessed by a contrasting 
CT scan 1 month after therapy.20 Although not entirely
accurate, the absence of a contrasting uptake inside the
tumour reflects tumour necrosis, while the persistence of
a contrasting uptake indicates viable tumours and incom-
plete ablation. We assessed the efficacy of RFA by con-
trasting CT scans performed at 1-, 3-, and 6-months after
the procedure, in order to examine a more prolonged out-
come. Thereafter, patients were assessed by a contrasting
CT scan at a 6-month interval. Similar protocols for 
post-ablation assessment have been followed in previous
studies.21
Complications from RF ablation are not uncommon.
Mulier et al reviewed 3,670 patients after RFA; mortality
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Figure. Cumulative overall survival of patients after RFA.
and morbidity rates were 0.5% and 8.9%, respectively.10
Another multicentre survey on 582 hepatic tumours over
a 5-year period reported the mortality, major and minor
complication rates to be 1.4%, 5.7% and 6.3%, respectively.22
Significant risk factors associated with treatment mor-
bidity included hyperbilirubinaemia (> 20 μmol/L), mul-
tiple tumour nodules, surgical approach, and early
experience (< 50 cases).23 In the present study, we did not
observe procedure-related mortality. The immediate mor-
bidity rate was 6.3% (5/79). In the percutaneous group,
one patient developed a subcapsular haematoma and
another patient developed a sympathetic right pleural
effusion. Both situations resolved on conservative man-
agement. In the surgical group, one patient had minor
bleeding from the right adrenal bed and managed by 
plication. Another patient developed a superficial gastric
serosal burn after laparoscopic ablation of a left lateral
segment tumour, which was identified at the end of pro-
cedure and repaired. There was a single case of a 1° skin
burn from the ground-pad.
Needle track seeding in patients treated with percuta-
neous RFA has raised a great deal of concern. Bonatti 
et al reported a case of skin implant metastasis after 
percutaneous RFA for colorectal liver metastasis.24 Seed-
ing has also been described after percutaneous RFA for
hepatocellular carcinoma performed with a single cooled-
tip electrode.25 There are several postulations for this 
phenomenon: dissemination of tumour cells on retrac-
tion of the radiofrequency electrode, tumour cell spread
from needle track haemorrhage and cells extruded by an
increased intratumoural pressure during RFA.16 One
patient in our series suffered from needle track metastasis
9 months after percutaneous RFA for her colorectal liver
secondaries. She subsequently died of carcinomatosis. Our
practice to minimise this complication was to burn the
track within the liver parenchyma during withdrawal 
of the electrode under all circumstances, and to discourage
the use of percutaneous RFA for subcapsular lesions.
With regard to RFA treatment responses and out-
come, the follow-up period of this study was similar to
previous reports.2,21,26,27 Complete ablation was achieved
in 81.1% (percutaneous) and 83.3% (surgical), without a
significant difference between the two approaches. This
result is comparable to international figures, in the region
of 80%.16,21 Some authors quoted a higher rate of com-
plete ablation by the open surgical approach than by the
percutaneous approach,21,26 possibly related to longer
ablation times with better pain tolerances under general
anaesthesia in the surgical group. Being unable to achieve
a complete ablation is usually related to a failure in the
RFA technique. Larger tumours need multiple overlapping
zones to cover adequate ablation margins in 3 dimensions.
We collaborated with senior radiologists in the intra-
operative tumour localisation until our technique matured.
Recurrence at extrahepatic sites (as well as distant site
intrahepatic recurrence), on the other hand, is more deter-
mined by the tumour biology and the natural history 
of the disease. The incidence varies among individual
studies.6,27 This illustrates the inability of local ablative
therapy in controlling the disease progression as a whole.
Again, we observed no significant difference in both
approaches (16.7% percutaneous vs. 17.1% surgical). In
terms of survival, 1-year and 2-year survival rates were
93.7% and 74.4%, respectively. These figures were similar
to the survival data reported by Rossi et al.28 Data on
longer-term outcome and survival are still lacking.
In conclusion, this study demonstrated that RFA is 
a safe and effective procedure for treating unresectable
primary or secondary liver malignancies. We did not
observe any significant difference in terms of recurrence
rate or survival outcome between the percutaneous and
surgical groups, although the two groups were not totally
comparable. The length of hospital stay is significantly
shorter in the percutaneous group, but concomitant
operations can be performed in the surgical group. 
A more prolonged follow-up study is required to assess
the longer-term outcomes.
Acknowledgements
We would like to express our gratitude to the S K Yee
Medical Foundation, Hong Kong, for the generous sup-
port in this program which is granted for RFA related
research and study.
References
1. Bruix J, Sherman M. Management of hepatocellular carcinoma.
Hepatology 2005;42:1208–36.
2. Salama HM, Hassan NHA, Hassan EM, et al. Percutaneous
radiofrequency ablation of hepatocellular carcinoma using a
multiple array needle electrode. HPB 2003;5:11–8.
3. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Compari-
son of resection and radiofrequency ablation for treatment of
solitary colorectal liver metastasis. Br J Surg 2003;90:1240–3.
■ PRELIMINARY RESULTS ON PERCUTANEOUS AND SURGICAL RFA APPROACHES ■
ASIAN JOURNAL OF SURGERY VOL 32 • NO 1 • JANUARY 2009 19
4. Izzo F, Barnett CC Jr, Curley SA. Radiofrequency ablation of pri-
mary and metastastic malignant liver tumors. Adv Surg 2001;
35:225–50.
5. Curley SA. Radiofrequency ablation of malignant liver tumours.
Oncologist 2001;6:14–23.
6. Ng KK, Poon RT. Radiofrequency ablation for malignant liver
tumor. Surg Oncology 2005;14:41–52.
7. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver
tumours: influence of technique and tumor size. Surgery 2002;
132:605–11.
8. Yokoyama T, Egami K, Miyamoto M, et al. Percutaneous and
laparoscopic approaches of radiofrequency ablation treatment
for liver cancer. J Hepatobiliary Pancreat Surg 2003;10:425–7.
9. Chen MS, Li JQ, Zheng Y, Guo RP, et al. A prospective random-
ized trial comparing percutaneous local ablative therapy 
and partial hepatectomy for small hepatocellular carcinoma.
Ann Surg 2006;243:321–8.
10. Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency
coagulation of liver tumours. Br J Surg 2002;89:1206–22.
11. Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular
acrcinoma: an audit of 343 patients. Ann Surg 1995;221:291–8.
12. Steele J, Strangl R, Altendorf-Hofmann A, et al. Resection of 
colorectal liver metastasis. World J Surg 1995;19:59–71.
13. Sutherland LM, Williams JAR, Padbury RTA, et al. Radio-
frequency ablation of liver tumours. A systematic review. Arch
Surg 2006;141:181–90.
14. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular
carcinoma in cirrhosis: randomized comparison of radio-
frequency thermal ablation versus percutaneous ethanol injec-
tion. Radiology 2003;228:235–40.
15. Crucitti A, Danza FM, Antinori A, et al. Radiofrequency thermal
ablation (RFA) of liver tumors: percutaneous and open surgical
approaches. Exp Clin Cancer Res 2003;22:191–5.
16. Jiao LR, Williamson RCN, Habib NA. Radiofrequency comes of
age in liver surgery: ablation technique and adjunct to resection.
HPB 2003;5:3–5.
17. Elias D, Debaere T, Muttillo I, et al. Intraoperative use of
radiofrequency treatment allows an increase in rate of curative
liver resection. J Surg Oncol 1998;67:190–1.
18. Evrard S, Becouarn Y, Fonck M, et al. Surgical treatment of liver
metastases by radiofrequency ablation, resection, or in combi-
nation. Euro J Surg Oncol 2004;30:399–406.
19. Shen P, Fleming S, Westcott C, et al. Laparoscopic radiofre-
quency ablation of the liver in proximity to major vasculature:
effect of the Pringle manoeuvre. J Surg Oncol 2003;83:36–41.
20. Bruix J, Sherman M, Llovet JM, et al. Clinical management of
hepatocellular carcinoma: conclusion of the Barcelona-2000
EASL Conference. J Hepatol 2001;35:421–30.
21. Kaneko T, Sugimoto H, Tezel E, et al. Radiofrequency ablation
therapy for malignant hepatic tumours: comparison of two 
procedures. HPB 2003;5:19–26.
22. de Baere T, Risse O, Kuoch V, et al. Adverse events during
radiofrequency treatment of 582 hepatic tumors. Am J Roentgenol
2003;181:695–700.
23. Poon RT, Ng KK, Lam CM, et al. Learning curve for radiofre-
quency ablation of liver tumors: prospective analysis of initial
100 patients in a tertiary institution. Ann Surg 2004;239:441–9.
24. Bonatti H, Bodner G, Obrist P, et al. Skin implant metastasis
after percutaneous radio-frequency therapy of liver metastasis
of a colorectal carcinoma. Am Surg 2003;69:763–5.
25. Llovet JM, Vilana R, Bru C, et al. Increased risk of tumour seed-
ing after percutaneous radiofrequency ablation for single hepa-
tocellular carcinoma. Hepatology 2001;33:1124–9.
26. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver
tumors: influence of technique and tumour size. Surgery 2002;
132:605–12.
27. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of
hepatocellular cancer in 110 patients with cirrhosis. Ann Surg
2000;232:381–91.
28. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF intersti-
tial thermal ablation in the treatment of hepatic cancer. Am J
Roentgenol 1996;167:759–68.
■ WONG et al ■
20 ASIAN JOURNAL OF SURGERY VOL 32 • NO 1 • JANUARY 2009
